ArticleDrug delivery2020
DEC-205 receptor-mediated long-circling nanoliposome as an antigen and
Article in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Liposomal Delivery Systems for Allergen-Specific Immunotherapy: From Molecular Design to Clinical Application.Membranes · 2026Review
- Graphene quantum dot-coated mesoporous silica loaded with glucosamine sulfate as a potent antigen delivery system for immunoactivation.Communications biology · 2026Article
- Advancing precision tumor therapy: Progress in targeted delivery of peptide-based nanomaterials from microenvironment to organelles.Materials today. Bio · 2026Review
- Physicochemical properties, biological activities, applications, and protective potential of the skeletal system ofFrontiers in pharmacology · 2025Review
- Advances inFrontiers in pharmacology · 2024Review
- Research Progress of Dendritic Cell Surface Receptors and Targeting.Biomedicines · 2023Review
- Eucommia Polysaccharides Ameliorate Aging-Associated Gut Dysbiosis: A Potential Mechanism for Life Extension in Drosophila.International journal of molecular sciences · 2023Article
- Research progress of nanovaccine in anti-tumor immunotherapy.Frontiers in oncology · 2023Review
- Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- DietaryAnimals : an open access journal from MDPI · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DEC-205 receptor-mediated dendritic cells (DC) targeting nanoliposomes is a promising delivery system in eliciting an immune response against pathogens. When this delivery system carries both antigen and immunomodulator, it can effectively regulate the DC function as well as the initial T cell response. To maximize the desired therapeutic effects of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.